Acute Coronary Syndrome Clinical Trial
— TIDES-OCTOfficial title:
A Randomized Prospective Multicenter Trial to Compare Vascular Healing and Vasodilation at 2 Months After Deployment of TItanium-nitride-oxide-coated OPTIMAX™ Stent and PROMUS-ELEMENT™ Drug-Eluting Stent in Patients With Acute Coronary Syndromes by Means of Optical Coherence Tomography and Coronary Flow Reserve
Verified date | October 2014 |
Source | The Hospital District of Satakunta |
Contact | n/a |
Is FDA regulated | No |
Health authority | Finland: Institutional review board |
Study type | Interventional |
The purpose of this study is to compare vascular healing of the stented segment after
deployment of titanium-nitride-oxide coated cobalt-chromium Optimax™-stent stent and
Promus-Element™ everolimus-eluting stent in patients with acute coronary syndromes requiring
percutaneous coronary intervention.
1. Comparison of OCT and CFR findings of titanium-nitride-oxide coated cobalt-chromium
Optimax™-stent and Promus-Element™ everolimus-eluting stent at two months after the
index procedure.
2. Comparison of intravascular coronary flow reserve measurement to non-invasive
transthoracic echocardiography-derived coronary flow reserve measurement.
3. Comparison of epicardial vasodilation to coronary microcirculatory vasodilation
Status | Completed |
Enrollment | 40 |
Est. completion date | January 2014 |
Est. primary completion date | December 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: 1. Age >18 and <80 years 2. STEMI or NSTEMI (assumed by investigator to be type 1 myocardial infarction, according to universal definitions of MI; EHJ 2007; 28(20):2525-38); or unstable angina (clinical symptoms of chest pain, ecg suggestive of reversible ischemia) 3. Patient is willing to comply with specified follow-up evaluations 4. Patient or legally authorized representative has been informed of the nature of the study, agrees to its provisions and has been provided written informed consent, approved by the appropriate Medical Ethics committee or Institutional Review Board 5. Single de novo or non-stented restenosis lesion 6. Patients with two-vessel disease may have undergone successful treatment of the non-target vessel with approved devices up to and including the index procedure but must be prior to the index target vessel treatment 7. Target lesion (maximum 20 mm length by visual estimation) to be covered by a single stent of maximum 23mm length 8. Reference vessel diameter must be >2.5mm and <4.0mm by visual estimate. 9. The vessel diameter should be measured after pre-dilation procedure and after intracoronary nitroglycerin if vasospasm is suspected 10. Target lesion >50% and <100% stenosed by visual estimate Exclusion Criteria: 1. Pre-existing diagnosis of diabetes irrespective of its type 2. Impaired renal function (serum creatinine >177micromol/l) or on dialysis 3. Platelet count < 10 e5 cells/mm3 4. Patient has a history of bleeding diathesis or coagulopathy or patients in whom antiplatelet and and/or anticoagulation therapy is contraindicated 5. Patient has received organ transplant or is on a waiting list for any organ transplant 6. Patient has a known hypersensitivity or contraindication to aspirin, heparin/bivalirudin, clopidogrel/prasugrel, stainless steel alloy, or contrast agent that cannot be adequately pre-medicated 7. Patient presents with cardiogenic shock 8. Any significant medical condition which in the Investigator's opinion may interfere with the patient's optimal participation in the study 9. Currently participating in another intestigational drug or device study 10. Unprotected left main disease 11. Ostial target lesions 12. Chronic total occlusion 13. Calcified target lesions that cannot be adequately pre-dilated 14. Target lesion has excessive tortuosity unsuitable for stent delivery and deployment 15. Target lesion involving bifurcation with a side branch larger than 2.0mm in diameter 16. A >30% stenosis proximal or distal to the target lesion that cannot be covered with the same stent 17. Diffuse distal disease 18. Prior stent in the target vessel |
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Finland | Kokkola Central Hospital | Kokkola | |
Finland | Heart Center, Kuopio University Hospital | Kuopio | |
Finland | Heart Center, Satakunta Central Hospital | Pori | |
Finland | Heart Center, Turku University Hospital | Turku |
Lead Sponsor | Collaborator |
---|---|
The Hospital District of Satakunta |
Finland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of uncovered struts | 2 months | No | |
Secondary | Coronary flow reserve | 2 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06013813 -
Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT05412927 -
AngelMed Guardian® System PMA Post Approval Study
|
||
Completed |
NCT02750579 -
Early or Delayed Revascularization for Intermediate and High-risk Non ST-elevation Acute Coronary Syndromes?
|
N/A | |
Completed |
NCT04102410 -
Assessing Force-velocity Profile: an Innovative Approach to Optimize Cardiac Rehabilitation in Coronary Patients
|
N/A | |
Enrolling by invitation |
NCT03342131 -
Serum Concentration of Wnt2 and Wnt4 in Patients With Acute Coronary Syndrome
|
N/A | |
Recruiting |
NCT01218776 -
International Survey of Acute Coronary Syndromes in Transitional Countries
|
||
Enrolling by invitation |
NCT04676100 -
International CR Registry
|
||
Completed |
NCT03590535 -
5th Generation cTnT in ED ACS
|
||
Recruiting |
NCT05437900 -
INSIGHTFUL-FFR Clinical Trial
|
Phase 4 | |
Completed |
NCT05551429 -
Factors Related to Participation in Cardiac Rehabilitation in Patients With Acute Coronary Syndrome
|
||
Terminated |
NCT04316481 -
IDE-ALERTS Continued Access Study
|
N/A | |
Active, not recruiting |
NCT04475380 -
Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
|
||
Not yet recruiting |
NCT04852146 -
Electronic Feedback for Data Restitution and Valorization to the Emergency Teams in Aquitaine.
|
||
Active, not recruiting |
NCT02892903 -
In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes?
|
N/A | |
Not yet recruiting |
NCT02871622 -
BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM
|
N/A | |
Completed |
NCT02944123 -
Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR)
|
Phase 3 | |
Completed |
NCT04077229 -
Piloting Text Messages to Promote Positive Affect and Physical Activity
|
N/A | |
Active, not recruiting |
NCT02922140 -
The Impact of Pharmaceutical Care Practice on Patients in Cardiac Rehabilitation Unit
|
N/A | |
Completed |
NCT02673437 -
Rivaroxaban ACS Specialist Cohort Event Monitoring Study
|